

Sample Received: **April 15, 2026**

COA Issued: **June 6, 2026**

## PRODUCT INFORMATION

Vendor: **Neurovia**      Sample Name: **Libido Drive**      Sample Type: **Capsule**      Lot Number: **LIBIDOCAP4-2026**      MW (g/mol): **1007, 1025, 1302, 3325**

## ANALYTICAL METHODS

**Identity:** Confirmed via MALDI-MS



**Purity:** RP-HPLC (214 nm)

**Content:** HPLC quantitation

## TEST RESULTS

Specification	Result	Method	Status
Identity: Libido Drive (PT-141, Oxytocin, N Acetyl L, Kisspeptin, VIP)	PT-141, Oxytocin, Kisspeptin, VIP	MALDI-MS	✓ Conforms
Content		HPLC Quantitation	✓ Conforms
Overall Purity	99.8%	RP-HPLC (214 nm)	✓ Conforms
Endotoxin	<0.05 EU/mL	<USP85>	✓ Conforms
Heavy Metals	<0.001 ppm	<USP232>	✓ Conforms

HPLC Chromatogram (Retention Time: 2.175, 2.583, 6.717, 7.900 min)



**Certification:** This COA confirms that the tested material meets or exceeds Bioviridian's analytical quality specifications for peptide research use.

Visit: <https://bioviridians.com/coa-search.html>



*Shane Straight*

Shane Straight, M.S.  
Principal Chemist, Bioviridian Inc.